Compare

Ocular Therapeutix, Inc vs Agios Pharmaceuticals, Inc. vs Nektar Therapeutics vs Aytu Biopharma, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearOcular Therapeutix, Inc
OCUL
Agios Pharmaceuticals, Inc.
AGIO
Nektar Therapeutics
NKTR
Aytu Biopharma, Inc
AYTU
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenue$51.95M$54.03M$55.23M$57.57M
Revenue growth (YoY)-18.5%+48.0%-43.9%-13.3%
Gross margin87.3% (computed)88.3% (computed)n/a64.0%
Operating margin-519.8%-873.9%-253.7%-14.4%
Net margin-511.9%-764.0%-297.1%-24.8%
Net income-$265.94M-$412.78M-$164.08M-$14.25M
EPS (Diluted)-$1.42-$7.12-$9.73n/a
Operating cash flow-$204.88M-$372.98M-$208.51M$3.28M
Free cash flow-$216.89M-$377.29M-$208.68M$3.25M
Cash & equivalents$737.06M$89.13M$15.12M$26.31M
Total assets$808.06M$1.30B$280.41M$105.01M
Total liabilities$153.75M$104.11M$190.57Mn/a
Shareholders' equity$654.31M$1.19B$89.83M$35.27M
Return on year-end equity-40.6%-34.6%-182.6%-40.4%
Shares outstanding215.93M58.45M20.38M10.73M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearOcular Therapeutix, IncAgios Pharmaceuticals, Inc.Nektar TherapeuticsAytu Biopharma, Inc
Latest$51.95M
Ended 2025-12-31
$54.03M
Ended 2025-12-31
$55.23M
Ended 2025-12-31
$57.57M
Ended 2026-06-30
1 year earlier$63.72M
Ended 2024-12-31
$36.50M
Ended 2024-12-31
$98.43M
Ended 2024-12-31
$66.38M
Ended 2025-06-30
2 years earlier$58.44M
Ended 2023-12-31
$26.82M
Ended 2023-12-31
$90.12M
Ended 2023-12-31
$65.18M
Ended 2024-06-30
3 years earlier$51.49M
Ended 2022-12-31
$14.24M
Ended 2022-12-31
$92.06M
Ended 2022-12-31
$107.40M
Ended 2023-06-30
4 years earlier$43.52M
Ended 2021-12-31
$0
Ended 2021-12-31
$101.91M
Ended 2021-12-31
$96.67M
Ended 2022-06-30